CSS
URGN icon

Cubist Systematic Strategies’s UroGen Pharma URGN Stock Holding History

Cubist Systematic Strategies’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-218,837
Closed -$3M – 3592
2025
Q2 		$3M Buy
+218,837
New +$2.1M 0.01% 1336
2024
Q4 		– Sell
-13,361
Closed -$170K – 3591
2024
Q3 		$170K Sell
13,361
-31,588
-70% -$469K ﹤0.01% 2610
2024
Q2 		$754K Buy
44,949
+38,799
+631% +$552K 0.01% 1913
2024
Q1 		$92.3K Buy
6,150
+6,008
+4,231% +$98.2K ﹤0.01% 3286
2023
Q4 		$2.13K Sell
142
-129,930
-100% -$1.69M ﹤0.01% 3450
2023
Q3 		$1.82M Buy
130,072
+117,718
+953% +$1.89M 0.01% 1428
2023
Q2 		$128K Buy
+12,354
New +$136K ﹤0.01% 2942
2020
Q1 		– Sell
-1,478
Closed -$49K – 2470
2019
Q4 		$49K Buy
1,478
+1,079
+270% +$29.5K ﹤0.01% 2283
2019
Q3 		$10K Sell
399
-1
-0.3% -$33 ﹤0.01% 2146
2019
Q2 		$14K Sell
400
-10,838
-96% -$400K ﹤0.01% 2396
2019
Q1 		$415K Buy
11,238
+10,438
+1,305% +$438K 0.01% 1304
2018
Q4 		$34K Buy
800
+703
+725% +$31.6K ﹤0.01% 1909
2018
Q3 		$5K Sell
97
-6,597
-99% -$307K ﹤0.01% 1837
2018
Q2 		$333K Buy
+6,694
New +$390K 0.02% 1018

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Cubist Systematic Strategies's URGN Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 218,837 shares — an estimated $3M sold.

Cubist Systematic Strategies first reported a position in URGN in Q2 2018 and held it in 14 quarters. The position peaked at $3M in Q2 2025. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 218,837 UroGen Pharma shares in Q3 2025, an estimated $3M.
  • Cubist Systematic Strategies first reported a position in UroGen Pharma in Q2 2018 and held it in 14 quarters.
  • Cubist Systematic Strategies's UroGen Pharma position peaked at $3M in Q2 2025.
  • 161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.